Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies

Other users also viewed these articles

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies Sebastião Cezar Radominski, Mario Humberto Cardiel, Gustavo Citera, Annelise Goecke, Juan Jose Jaller, Andrea Barranjard Vannucci Lomonte, Pedro Miranda, Patricia Velez, Daniel Xibillé, Kenneth Kwok, Ricardo Rojo, Erika Gabriela García

10.1016/j.reumae.2016.04.015

Efficacy and Safety of Abatacept in Patients With Rheumatoid Arthritis and No Prior Treatment With Biologics Alejandro Escudero Contreras, M. Carmen Castro-Villegas, M. Vanesa Hernández-Hernández, Federico Díaz-González

10.1016/j.reumae.2011.11.001

Takotsubo Syndrome in a Rheumatoid Arthritis Patient Under Tofacitinib: A Case Report Salomé Garcia, Georgina Terroso, Elisabete Martins, Sofia Pimenta, Lúcia Costa, Miguel Bernardes

10.1016/j.reumae.2021.06.006